Sanguine CorporationCompany Review & Valuation

OTC Markets

About Sanguine Corporation

Sanguine Corporation, a development stage company, engages in the development and commercialization of perfluorocarbon based therapeutic oxygen carriers for use in the medical profession in the United States. The company primarily offers PHER-O2, a perflurcarbon emulsion under pre-clinical and cliniShow morecal testing, which consists of perfluoro-decalin molecules, purified water, and a proprietary surfactant to hold the emulsion together. Its PHER-O2 has applications in various medical indications, including transportation of pancreas islets for treatment of diabetes; ophthalmic retinal surgery; angioplasty; external oxygenation of infection, ischemic tissue, and diabetic ulcers; Alzheimer's disease; traumatic brain injury; oxygenation of cancerous tumors; nuclear magnetic resonance imaging; CAT scans; cardioplegia or the priming of heart-lung machines in open heart surgery; and treatment of heart attacks, strokes, head and neck tumors, and hemorrhagic shock. The company was formerly known as International Health Resorts, Inc. and changed its name to Sanguine Corporation in June 1993. Sanguine Corporation was founded in 1974 and is based in Roswell, Georgia.Show less

Diagnostic Substances
HQ Location
Roswell, Georgia

Stock Price

Price data not available for Sanguine Corporation.


Please login or create a free account to view the contents of this section.

Similar Companies

back to top